LON:SCLP Scancell (SCLP) Share Forecast, Price & News GBX 15.50 0.00 (0.00%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range 15.37▼ 15.6650-Day Range 14.25▼ 20.5052-Week Range 10.75▼ 29.40Volume199,193 shsAverage Volume761,369 shsMarket Capitalization£126.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Scancell (LON:SCLP) StockScancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.Read More Receive SCLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLP Stock News HeadlinesJune 2, 2023 | proactiveinvestors.comScancell updates on progress ahead of ASCO poster presentationApril 18, 2023 | proactiveinvestors.comScancell says its Head of Clinical Operations to make AACR poster presentationJune 6, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 16, 2023 | americanbankingnews.comScancell (LON:SCLP) Stock Crosses Below 200-Day Moving Average of $19.25March 13, 2023 | proactiveinvestors.comScancell has no exposure to Silicon Valley Bank, company assures stakeholdersMarch 13, 2023 | proactiveinvestors.comScancell Holdings had no exposure to Silicon Valley Bank, company assures stakeholdersFebruary 13, 2023 | proactiveinvestors.comScancell Holdings hails as 'highly encouraging' the results from phase I Covid studyFebruary 13, 2023 | proactiveinvestors.comScancell hails as 'highly encouraging' the results from phase I Covid studyJune 6, 2023 | UNKNOWN (Ad)Lithium Has Boomed And This American Stock Is Ready..Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!February 1, 2023 | proactiveinvestors.comScancell announces appointment of Dr Jean-Michel Cosséry as its non-executive chairman with immediate effectJanuary 27, 2023 | finance.yahoo.comEven though Scancell Holdings (LON:SCLP) has lost UK£33m market cap in last 7 days, shareholders are still up 217% over 3 yearsJanuary 25, 2023 | proactiveinvestors.comScancell hails period of clinical and commercial progressJanuary 22, 2023 | finance.yahoo.comScancell Holdings plc (SCLP.L)December 10, 2022 | msn.comIs the Scancell share price set to rocket in 2023?December 7, 2022 | uk.finance.yahoo.comWhy is the Scancell share price climbing?October 26, 2022 | proactiveinvestors.comScancell executive chairman John Chiplin to step downOctober 26, 2022 | proactiveinvestors.comScancell says executive chairman John Chiplin to step downOctober 25, 2022 | proactiveinvestors.comScancell signs exclusive deal with cancer giant Genmab for anti-glycan antibodyOctober 17, 2022 | yahoo.comSouth Korea kicks off military drills amid talk of North Korean nuclear test - Yahoo! VoicesOctober 17, 2022 | finance.yahoo.comHedge funds investors own a significant stake of 44% in Scancell Holdings plc (LON:SCLP)October 13, 2022 | streetinsider.comNAV Update - StreetInsider.comSeptember 23, 2022 | proactiveinvestors.comScancell to provide new insights on its monoclonal antibodies technology - Proactive Investors USAJune 23, 2022 | proactiveinvestors.comScancell targets emerging class of cancer treatment with latest addition to pipelineJune 16, 2022 | proactiveinvestors.comScancell Holdings expands its phase II trial of cancer drug SCIB1June 15, 2022 | marketscreener.comFTSE 100 Closed Higher on Expected Rise in Fed Interest Rates - Marketscreener.comJune 15, 2022 | marketscreener.comSterling Could Fall After BOE Decision - Marketscreener.comJune 15, 2022 | morningstar.comFTSE 100 Seen Higher With Fed Rate Decision In Focus - MorningstarSee More Headlines SCLP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCLP Company Calendar Last Earnings1/31/2020Today6/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SCLP CUSIPN/A CIKN/A Webwww.scancell.co.uk Phone+44-115-8231863FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-8,440,000.00 Net Margins-160.08% Pretax MarginN/A Return on Equity-44.27% Return on Assets-16.31% Debt Debt-to-Equity Ratio61.41 Current Ratio11.45 Quick Ratio13.01 Sales & Book Value Annual Sales£5.27 million Price / Sales24.07 Cash FlowGBX 1.97 per share Price / Cash Flow7.86 Book ValueGBX 2 per share Price / Book7.75Miscellaneous Outstanding Shares818,400,000Free FloatN/AMarket Cap£126.85 million OptionableNot Optionable Beta0.59 Key ExecutivesProf. Lindy Gillian Durrant Ph.D.Founder, CEO, Chief Scientific Officer & DirectorDr. Sally Elizabeth Adams (Age 61)Chief Devel. Officer & Director Comp: $255.65kMr. Keith GreenDirector of Fin. & Admin. and Company Sec.Dr. Samantha Paston Ph.D.Head of Translational ResearchDr. Adrian Parry Ph.D.Head of ManufacturingMs. Akua AsareHead of QualityMr. Fayaz MasterHead of Clinical OperationsMore ExecutivesKey CompetitorsTiziana Life SciencesLON:TILSVerseonLON:VSNAgronomicsLON:ANIChVIVOLON:HVOe-therapeuticsLON:ETXView All Competitors SCLP Stock - Frequently Asked Questions How have SCLP shares performed in 2023? Scancell's stock was trading at GBX 24.75 at the beginning of the year. Since then, SCLP shares have decreased by 37.4% and is now trading at GBX 15.50. View the best growth stocks for 2023 here. How were Scancell's earnings last quarter? Scancell Holdings plc (LON:SCLP) released its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) EPS for the quarter. Scancell had a negative net margin of 160.08% and a negative trailing twelve-month return on equity of 44.27%. What other stocks do shareholders of Scancell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU). What is Scancell's stock symbol? Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP." How do I buy shares of Scancell? Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Scancell's stock price today? One share of SCLP stock can currently be purchased for approximately GBX 15.50. How much money does Scancell make? Scancell (LON:SCLP) has a market capitalization of £126.85 million and generates £5.27 million in revenue each year. The company earns £-8,440,000.00 in net income (profit) each year or GBX (0.01) on an earnings per share basis. How can I contact Scancell? Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for the company is www.scancell.co.uk. The company can be reached via phone at +44-115-8231863. This page (LON:SCLP) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scancell Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.